You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379
|
|---|---|
| Published in |
Oncogene, January 2018
|
| DOI | 10.1038/s41388-017-0116-9 |
| Pubmed ID | |
| Authors |
K. P. O’Brien, S. Khan, K. E. Gilligan, H. Zafar, P. Lalor, C. Glynn, C. O’Flatharta, H. Ingoldsby, P. Dockery, A. De Bhulbh, J. R. Schweber, K. St John, M. Leahy, J. M. Murphy, W. M. Gallagher, T. O’Brien, M. J. Kerin, R. M. Dwyer |
| Abstract |
Adult Mesenchymal Stem Cells (MSCs) have a well-established tumor-homing capacity, highlighting potential as tumor-targeted delivery vehicles. MSCs secrete extracellular vesicle (EV)-encapsulated microRNAs, which play a role in intercellular communication. The aim of this study was to characterize a potential tumor suppressor microRNA, miR-379, and engineer MSCs to secrete EVs enriched with miR-379 for in vivo therapy of breast cancer. miR-379 expression was significantly reduced in lymph node metastases compared to primary tumor tissue from the same patients. A significant reduction in the rate of tumor formation and growth in vivo was observed in T47D breast cancer cells stably expressing miR-379. In more aggressive HER2-amplified HCC-1954 cells, HCC-379 and HCC-NTC tumor growth rate in vivo was similar, but increased tumor necrosis was observed in HCC-379 tumors. In response to elevated miR-379, COX-2 mRNA and protein was also significantly reduced in vitro and in vivo. MSCs were successfully engineered to secrete EVs enriched with miR-379, with the majority found to be of the appropriate size and morphology of exosomal EVs. Administration of MSC-379 or MSC-NTC cells, or EVs derived from either cell population, resulted in no adverse effects in vivo. While MSC-379 cells did not impact tumor growth, systemic administration of cell-free EVs enriched with miR-379 was demonstrated to have a therapeutic effect. The data presented support miR-379 as a potent tumor suppressor in breast cancer, mediated in part through regulation of COX-2. Exploiting the tumor-homing capacity of MSCs while engineering the cells to secrete EVs enriched with miR-379 holds exciting potential as an innovative therapy for metastatic breast cancer. |
X Demographics
The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 12 | 41% |
| United States | 2 | 7% |
| Belgium | 1 | 3% |
| Pakistan | 1 | 3% |
| Australia | 1 | 3% |
| United Kingdom | 1 | 3% |
| Malaysia | 1 | 3% |
| Spain | 1 | 3% |
| Unknown | 9 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 41% |
| Scientists | 12 | 41% |
| Science communicators (journalists, bloggers, editors) | 3 | 10% |
| Practitioners (doctors, other healthcare professionals) | 2 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 121 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 17% |
| Student > Master | 20 | 17% |
| Student > Bachelor | 14 | 12% |
| Researcher | 10 | 8% |
| Student > Doctoral Student | 7 | 6% |
| Other | 16 | 13% |
| Unknown | 33 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 33 | 27% |
| Medicine and Dentistry | 14 | 12% |
| Agricultural and Biological Sciences | 10 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Immunology and Microbiology | 5 | 4% |
| Other | 16 | 13% |
| Unknown | 36 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2018.
All research outputs
#1,335,613
of 25,250,629 outputs
Outputs from Oncogene
#234
of 11,081 outputs
Outputs of similar age
#31,275
of 453,766 outputs
Outputs of similar age from Oncogene
#10
of 116 outputs
Altmetric has tracked 25,250,629 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,081 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,766 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 116 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.